WO2022107108A1 - Encres à base de gomme gellane, leur procédé d'obtention et leurs utilisations - Google Patents
Encres à base de gomme gellane, leur procédé d'obtention et leurs utilisations Download PDFInfo
- Publication number
- WO2022107108A1 WO2022107108A1 PCT/IB2021/060867 IB2021060867W WO2022107108A1 WO 2022107108 A1 WO2022107108 A1 WO 2022107108A1 IB 2021060867 W IB2021060867 W IB 2021060867W WO 2022107108 A1 WO2022107108 A1 WO 2022107108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- gellan gum
- previous
- peptide
- cell
- Prior art date
Links
- 229920002148 Gellan gum Polymers 0.000 title claims abstract description 247
- 239000000216 gellan gum Substances 0.000 title claims abstract description 243
- 235000010492 gellan gum Nutrition 0.000 title claims abstract description 243
- 238000000034 method Methods 0.000 title claims description 29
- 239000000976 ink Substances 0.000 title description 166
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 134
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000018417 cysteine Nutrition 0.000 claims abstract description 23
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 86
- 210000004027 cell Anatomy 0.000 claims description 73
- 239000000017 hydrogel Substances 0.000 claims description 64
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 25
- 210000000130 stem cell Anatomy 0.000 claims description 19
- 238000003860 storage Methods 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 238000010146 3D printing Methods 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 11
- 239000006143 cell culture medium Substances 0.000 claims description 11
- 239000008188 pellet Substances 0.000 claims description 10
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000002953 phosphate buffered saline Substances 0.000 claims description 7
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 claims description 5
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- -1 Tris-acetate-EDTA Chemical compound 0.000 claims description 5
- 210000004102 animal cell Anatomy 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 108010008488 Glycylglycine Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 3
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 claims description 3
- 206010072170 Skin wound Diseases 0.000 claims description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 3
- 239000007997 Tricine buffer Substances 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000002221 antipyretic Substances 0.000 claims description 3
- 229940125716 antipyretic agent Drugs 0.000 claims description 3
- 239000007998 bicine buffer Substances 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 102000018997 Growth Hormone Human genes 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 229940124326 anaesthetic agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000036560 skin regeneration Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 52
- 239000000463 material Substances 0.000 description 27
- 238000004132 cross linking Methods 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 19
- 239000004971 Cross linker Substances 0.000 description 18
- 238000001125 extrusion Methods 0.000 description 18
- 238000007639 printing Methods 0.000 description 18
- 230000002500 effect on skin Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 11
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000017423 tissue regeneration Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000011069 regeneration method Methods 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 239000012620 biological material Substances 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000001857 anti-mycotic effect Effects 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000002543 antimycotic Substances 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000001879 gelation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 238000006065 biodegradation reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 230000004956 cell adhesive effect Effects 0.000 description 4
- 238000011960 computer-aided design Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100027995 Collagenase 3 Human genes 0.000 description 3
- 108050005238 Collagenase 3 Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241000237536 Mytilus edulis Species 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000020638 mussel Nutrition 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000008000 CHES buffer Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 108010019116 resilin Proteins 0.000 description 2
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000790234 Sphingomonas elodea Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001718 carbodiimides Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000012881 co-culture medium Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 description 1
- 108010057670 laminin 1 Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000010872 live dead assay kit Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 108010004563 mussel adhesive protein Proteins 0.000 description 1
- 239000003988 mussel adhesive protein Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical group OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D11/00—Inks
- C09D11/02—Printing inks
- C09D11/04—Printing inks based on proteins
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D11/00—Inks
- C09D11/02—Printing inks
- C09D11/14—Printing inks based on carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- the present disclosure relates to bio-instructive gellan gum-based inks, the method of preparation and uses thereof.
- 3D bioprinting is a technology capable of building complex engineered 3D living tissues.
- 3D bioprinting uses a computer-aided design (CAD) to generate 3D models that are then reproduced into an object through layer-by-layer deposition.
- the object is printed using a biomaterial solution - the ink - or a biomaterial solution containing cells - the bioink.
- CAD computer-aided design
- Extrusion-based printers are commonly used to bioprint 3D living tissues. Extrusion-based printers are composed of one/multiple printhead(s) holding a syringe where the ink/bioink is loaded. When a mechanical force or pneumatic pressure is applied, the ink/bioink is extruded through a needle coupled to the syringe, being dispensed as a fibre into a platform. In order to guarantee this extrusion through the needle without occluding it and causing shear stress to the encapsulated cells, while printing a fiber with shape-fidelity, the ink/bioink must have adequate rheological properties. This also determines the mechanical stability of the whole 3D structure postprinting.
- Inks with cell adhesive features are beneficial as they provide specific sites for encapsulated cells to adhere, further supporting the proliferation, differentiation/maturation of the printed cells and the generation of a matured tissue.
- inks composed of biomaterials chemically functionalized with cell adhesive sites are of interest for the printing of cell-laden 3D structures aimed at acting as tissue-like analogues either as in vitro models or as substitutes for tissue regeneration.
- GG Gellan gum
- GG is an exocellular polysaccharide produced by aerobic submerged fermentation of Sphingomonas elodea.
- GG is a linear and anionic polymer composed of repeating units of a tetrasaccharide (1,3- -D-glucose, 1,4- -D-glucuronic acid, 1,4- -D-glucose, 1,4-a-L- rhamnose).
- GG is termed thermoreversible as it responds to temperature decrease with a sol-gel transition.
- GG has a thermally reversible coil form at high temperatures which, upon temperature decrease down to 37°C, changes to a double-helix form. Then, a structure composed of anti-parallel double helices is self-assembled, forming oriented bundles, called junction zones. The junction zones link untwined regions of extended helical chains, leading to the formation of a hydrogel.
- counter ions specifically monovalent or divalent cations, promotes a physical bonding between cations and carboxylate groups of the GG, particularly strong when involving divalent ions, leading to the formation of the 3D and crosslinked hydrogel. This allows the formation of GG hydrogels at mild and bio-friendly conditions.
- Gellan gum exists in two different forms, the high-acyl and the low-acyl forms.
- high-acyl gellan gum the acyl residues are located on the periphery of the helix, obstructing the polymer chain association, resulting in soft, elastic and non-brittle gels.
- low-acyl gellan gum produces firm, non-elastic, brittle hydrogels since ions can easily link polymer chains and form a branched polymeric network.
- Document EP2244753A2 discloses the processing and application of gellan gum for regenerative medicine and tissue engineering approaches, focusing on processes for packaging, handling, processing of different structures, controlled anionic crosslinking, as well as its combination with biomolecules and/or live cells in order to reduce the variability in its chemical and physical properties and in the generated biological results, increasing their effectiveness in the regeneration of living tissues in cellular tests before and/ or after implantation in animals and/or humans. This document does not make reference to the printing of gellan gum.
- Proton NMR demonstrated an efficiency of modification of GG to divinyl sulfone (DVS) of 50% and protein quantification analysis identified an efficiency of modification of GGDVS to CTTSWSQCSKS of 100% and to CGGKAFDITYVRLKF of 20%.
- GGDVS was also crosslinked with the dithiol peptide CRDGPQGIWGQDRC.
- the peptides linked to the modified gellan gum described in this document are different from the peptides described in the present invention. Moreover, this document does not make reference to the printing of modified gellan gum.
- Document CN106474560A discloses a kind of hydrogel material for 3D bioprinting and a preparation method and application of the hydrogel material.
- the ink comprises the following in percentages by mass: 0.5-10% of gellan gum and/or derivatives, 0.1-20% of polyethylene glycol (PEG) and/or derivatives thereof, 0-1% of a crosslinking initiator, 0-15% of biologically active components and the balance of a solvent.
- the printed hydrogel is a double-network hydrogel based on the gellan gum and PEG; interpenetrating double-network structures are formed in a physiological environment; and the printed hydrogel has good structure and dimensional stability, and has the advantages of quick gum formation under physiological conditions, excellent cell compatibility, small immunological rejection, high cell encapsulation efficiency, controllable mechanical strength, and biodegradability.
- This document describes a hydrogel material that contains PEG.
- the ink described in the present invention does not contain PEG.
- Document WO2018/191244A1 discloses the composition for a polysaccharide hydrogel comprising: one or more water soluble high acyl gellan gum polymers; one or more water soluble low acyl gellan gum polymers; and one or more water soluble chemically modified gellan gum polymers or one or more peptide modified gellan gum polymers.
- One or more bioactive molecules are added to the gellan gum solution before heating, being then dispersed within the polymer chains but not chemically linked to the polymer, and are selected from the group consisting of: cells, peptides, functional peptide molecules with NH2, COOH and CONH2 group comprising: RGD, IKVAV, REDV, YIGSRY, poly Lysine.
- the polysaccharide hydrogel is used as a versatile platform for drug discovery and biomedical applications, comprising cell viability assay, live/dead assay, high-throughput screening, fluorescent staining and imaging, histological analysis, and 3D bio-printing.
- This document describes a polysaccharide hydrogel containing high acyl GG, low acyl GG and chemically modified GG, wherein the chemically modified GG results from the mixing (not chemical tethering) of the GG with a bioactive molecule.
- the present invention describes an ink containing any GG (low acyl or high acyl) wherein at least 0.1 % (m/v) of the gellan gum is chemically modified with divinyl sulfone and is chemically linked to any cysteine-containing peptide.
- Document "3D printing of layered brain-like structures using peptide modified gellan gum substrates” from Lozano et al. (2015) describes a method to bioprint 3D brain-like structures consisting of discrete layers of primary cortical neurons encapsulated in GG-RGD hydrogels.
- GG was chemically modified with GGGGRGDSY peptide using the EDC/Sulfo-NHS chemistry reaction. The efficiency of conjugation was not determined.
- Bioprinted primary cortical neurons in GG-RGD hydrogels showed a spread morphology with extended neurites. However, the ink takes a long time to be prepared (approximately 8 days). After the chemical modification, the material needs to be dissolved overnight at 60°C, prior printing.
- the modification of gellan gum and the linked peptide described in this document are different from the modification and the linked peptide described in the present invention.
- Document KR20180035162A discloses a bio-ink for 3D bio-printing and its use, and a method for producing a bio-ink comprising a natural polymer with a mussel adhesive protein or a variant thereof and performing a cross-linking reaction.
- a mussel adhesive peptide, not a protein is linked, not crosslinked, to a chemically modified GG, not a natural polymer.
- the present disclosure relates to bio-instructive gellan gum-based inks, the method of preparation and uses thereof.
- Bio-instructive gellan gum-based inks comprise a gelifying material and a bio- instructive material. Surprisingly, the combination of cells with the gelifying material and the bio-instructive material resulted in a stable bioink, with suitable properties for bioprinting (e.g. rheologic properties), and lead to an improved biological performance, as showed in Figures 9-13.
- the present disclosure relates to a printable ink comprising 0.5 to 2.5 % (m/vink) of a gellan gum, comprising at least 0.1 % - 2.5 % (m/vink) of divinyl sulfone-modified gellan gum and 0 to 2.4 % (m/vink) of unmodified gellan gum; and 0.0002 to 20 M of a peptide sequence containing cysteine, wherein the peptide is chemically linked to the gellan gum via the divinyl sulfone moieties.
- the divinyl sulfone-modified gellan gum is a gellan gum chemically modified with divinyl sulfone groups.
- This divinyl sulfone-modified gellan gum can be produced as described in the begin of section 5 of the document "Gellan Gum Hydrogels with Enzyme-Sensitive Biodegradation and Endothelial Cell Biorecognition Sites" from da Silva et al. (2018).
- An aspect of the present disclosure describes an ink comprising:
- a gellan gum 0.5 to 2.5 % (m/vink) of a gellan gum, wherein at least 0.1 % (m/vink) of the gellan gum is modified with divinyl sulfone; and a peptide sequence containing a cysteine, wherein the peptide is linked to the gellan gum via the divinyl sulfone moieties.
- the ink comprises 0.75 to 2 % (m/vink) of a gellan gum, wherein 0.25 to 2 % (m/vink) of divinyl sulfone-modified gellan gum; and a peptide sequence containing cysteine, wherein the peptide is linked to the gellan gum via the divinyl sulfone moieties.
- the ink comprises 1.5 % (m/vink) of a gellan gum, wherein 0.5 % (m/vink) of gellan gum is modified with divinyl sulfone; and a peptide sequence containing cysteine, wherein the peptide is linked to the gellan gum via the divinyl sulfone moieties.
- the ink comprises 0.75 % (m/vink) of a gellan gum, wherein 0.25% (m/vink) of gellan gum is modified with divinyl sulfone; and a peptide sequence containing cysteine, wherein the peptide is linked to the gellan gum via the divinyl sulfone moieties.
- the ink comprises 1.125 % (m/vink) of a gellan gum, wherein 0.375% (m/vink) of gellan gum is modified with divinyl sulfone; and a peptide sequence containing cysteine, wherein the peptide is linked to the gellan gum via the divinyl sulfone moieties.
- the ink comprises 1.875 % (m/vink) of a gellan gum, wherein 0.625% (m/vink) of gellan gum is modified with divinyl sulfone; and a peptide sequence containing cysteine, wherein the peptide is linked to the gellan gum via the divinyl sulfone moieties.
- the ink comprises 1.5 % (m/vink) of a gellan gum, wherein 1.5% (m/vink) of gellan gum is modified with divinyl sulfone; and a peptide sequence containing cysteine, wherein the peptide is linked to the gellan gum via the divinyl sulfone moieties.
- the peptide sequence comprises at least a sequence 90% identical to the sequences of the following list: SEQ. ID No 1, SEQ. ID No 2, SEQ. ID No 3, SEQ. ID No 4, SEQ. ID No 5, SEQ ID No 6, SEQ. ID No 7, SEQ. ID No 8, SEQ. ID No 9, SEQ. ID No 10, SEQ. ID No 11, SEQ. ID No 12, SEQ. ID No 13, SEQ. ID No 14, SEQ. ID No 15, SEQ. ID No 16, SEQ. ID No 17 or mixtures thereof.
- the peptide concentration ranges from 0.0002 to 20M, preferably 0.0007 to 15 M.
- the degree of modification of the divinyl sulfone- modified gellan gum ranges from 5 to 100%, preferably 25 to 100%.
- the gellan gum is a high acyl gellan gum, low acyl gellan gum or mixtures thereof.
- the concentration of unmodified gellan gum ranges from 0.4 to 2.4 % (m/vink), preferably from 0.5 to 1.25 % (m/vink).
- the concentration of the divinyl sulfone-modified gellan gum ranges from 0.1 to 2.5 % (m/vink), preferably from 0.25 to 1 % (m/vink), more preferably from 0.4 to 0.625 % (m/vink).
- the volume ratio between the unmodified gellan gum and the divinyl sulfone-modified gellan gum is 0.5:1 to 1:0.5, preferably 1:1.
- the mass ratio between the unmodified gellan gum and the gellan gum-divinyl sulfone is 2:1 to 1:2, preferably 2:1.
- the ink further comprises an antiseptic agent, an antipyretic agent, an anaesthetic agent, a therapeutic agent, a cell, a growth factor, an antibody, an antibiotic, an anti-microbial agent, an anti-fungi agent, an antimycotic agent, an antiinflammatory agent, an enzyme, a metallic element, a growth hormone, a cytokine, an interleukin, a chemokine, an angiogenic factor, an anti-angiogenic factor, an anticoagulant, a contrasting agent, a chemotherapeutic agent, a signaling pathway molecule, a cell receptor, a cell ligand, or combinations thereof.
- an antiseptic agent an antipyretic agent, an anaesthetic agent, a therapeutic agent, a cell, a growth factor, an antibody, an antibiotic, an anti-microbial agent, an anti-fungi agent, an antimycotic agent, an antiinflammatory agent, an enzyme, a metallic element, a growth hormone, a cytokine, an interleuk
- the cell is a non-human animal cell, a human cell, a stem cell, a cell line, a primary cell, a progenitor cell or mixtures thereof.
- the viscosity at 37°C ranges from 0.01 to 300000 Pa.s, preferably from 1.00 - 200 000 Pa.s, more preferably from 100 - 100 000 Pa.s.
- the shear storage modulus of the ink decreases by increasing the temperature. In a further embodiment, the shear storage modulus of the ink decreases by increasing the temperature above 30°C.
- the ink is converted into a hydrogel by decreasing temperature, upon contact with a cysteine containing peptide and/or upon contact with aqueous ionic solutions, preferably phosphate buffered saline, cell culture media, or mixtures thereof.
- the ink is converted into a hydrogel by decreasing the temperature bellow 90°C, preferably bellow 40°C.
- the ink is converted into a hydrogel at a temperature ranging from 4°C to 90°C, preferably from 4°C to 50°C, more preferably 30°C to 50°C.
- the cysteine containing peptide is selected from the following list: SEQ. ID No 8, SEQ. ID No 9, SEQ. ID No 10, SEQ. ID No 11, SEQ. ID No 12, SEQ. ID No 13, SEQ. ID No 14, SEQ. ID No 15, SEQ. ID No 16, SEQ. ID No 17, or mixtures thereof.
- the ink is converted into a stable hydrogel by contact with aqueous ionic solutions, preferably phosphate buffered saline, cell culture media, or mixtures thereof.
- aqueous ionic solutions preferably phosphate buffered saline, cell culture media, or mixtures thereof.
- the shear storage modulus after the conversion of the ink into a stable hydrogel ranges from 10 to 10000 Pa, preferably from 150 to 10000 Pa.
- An aspect of the present disclosure comprises the use of the ink as a 3D printable ink and/or bioink.
- the present disclosure also relates to an article comprising a stable hydrogel obtainable from the ink described in any of the previous embodiments, preferably an article obtained by 3D printing.
- the article is a hydrogel or a three-dimensional dried polymer matrix.
- the peptide sequence can be an artificial sequence.
- the article is for use in tissue engineering or regenerative medicine.
- the ink is for use in skin repair or skin regeneration.
- the ink is for use in the therapy or treatment of skin wounds.
- the present disclosure also relates to a kit comprising the ink described in any of the previous embodiments.
- the ink can be in a reservoir configured to be used in a 3D printer.
- a method of preparing the ink comprising the following steps: (i) dissolving a divinyl sulfone-modified gellan gum in distilled water or a suitable buffer with pH above 8.2, preferably in distilled water containing 0.5M of sucrose; (ii) reacting the dissolved divinyl sulfone-modified gellan gum with a peptide sequence for 1 hour at 20-25°C, preferably 25°C; (iii) optionally, dissolving an unmodified gellan gum in a suitable buffer, preferably in distilled water, at 90°C under stirring for 15-60 minutes, preferably for 30 minutes, and mixing the dissolved gellan gum with the dissolved divinyl sulfone-modified gellan gum reacted with a peptide sequence, in a 1:1 (v:v) ratio, at a temperature between 4-50°C.
- the method further comprises the step of mixing the peptide- containing gellan gum mixture with a cell pellet or a solution containing cells, at a temperature between 4-45°C, preferably between 4 to 37°C, more preferably at 37°C.
- the cell pellet or the solution containing cells comprises non-human animal cells, human cells, stem cells, cell lines, primary cells, progenitor cells or mixtures thereof.
- the suitable buffer is selected from the following list: Triethanolamine, Tris-acetate-EDTA, Tris base, tricine, bicine, diglycine, 4-(2- Hydroxyethyl)-l-piperazinepropanesulfonic acid, 4-(2-Hydroxyethyl)piperazine-l- propanesulfonic acid, N-(2-Hydroxyethyl)piperazine-N'-(3-propanesulfonic acid) (HEPES), N-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid, [(2-Hydroxy-l,l- bis(hydroxymethyl)ethyl)amino]-l-propanesulfonic acid (TAPS), 2-Amino-2-methyl-l,3- propanediol, Ammediol (AMPD), N-(l,l-Dimethyl-2-hydroxyethyl)-3-amino-2- hydroxypropanesulfonic acid
- the bio-instructive gellan gum-based ink alone, or in combination with cells can be used to print bio-instructive biomaterials or tissue-like substitutes for the repair/regeneration of tissue defects or/and of diseased tissues or/and organs, such as for the treatment of wounds.
- bio-instructive gellan gum-based ink alone, or in combination with cells can be used to print tissues or/and organ models for the in vitro study of diseases or/and drug screening.
- Figure 1 shows the rheological behaviour of different GG/GGDVS, GG/GGDVS- SEQ. ID No 2 and GGDVS inks, which composition is described in Table 1 and Table 2.
- Representative shear rate ramps of a) GG/GGDVS, c) GG/GGDVS-SEQ. ID No 2 and e) GGDVS inks at 10 and 15 mg/mL are shown.
- the shear viscosity was monitored for shear rates between 0.1 and 100 s’ 1 , at 37°C.
- Representative shear stress ramps of b) GG/GGDVS inks, d) GG/GGDVS-SEQ. ID No 2 and f) GGDVS inks are shown.
- Figure 2 shows the rheological behaviour of formulations a) A, b) B, c) C and d) D of GG/GGDVS inks, which composition is described in Table 1, at decreasing temperatures.
- the shear storage (G') and loss (G") moduli were recorded within a temperature ramp ranging from 60°C to 5°C (2°C min -1 ), with constant shear of 1.6 Hz and 0.5 % target shear strain.
- Figure 3 shows the rheological behavior of GGDVS inks crosslinked with the SEQ. ID No 14 peptide, which composition is described in Table 8 and 9. Representative time sweeps of GGDVS inks are shown. The storage modulus was recorded in a time sweep at 37°C, with constant shear of 1.6 Hz and 0.5 % target shear strain. G" modulus values ranged between 1 and 5 Pa.
- Figure 4 plots an embodiment of the force needed to extrude GG/GGDVS inks at 37°C using a a) 20-gauge and b) 27-gauge needle. Similar results were achieved with the peptides of the present disclosure.
- Figure 5 shows an embodiment of fibres printed with GG/GGDVS inks in an extrusion-based printer. Similar results were achieved using inks containing the peptides of the present disclosure.
- Figure 6 shows an embodiment of 3D discs printed with GG/GGDVS inks in an extrusion-based printer. Similar results were achieved using inks containing the peptides of the present disclosure.
- Figure 7 shows the swelling ratio of GG/GGDVS, GG/GGDVS-SEQ. ID No 2, GG/GGDVS-SEQ. ID No 3, GG/GGDVS-SEQ. ID No 4, GG/GGDVS-SEQ. ID No 5 discs after immersion in a) phosphate buffered saline solution, b) calcium chloride, c) a-minimum essential medium (a-MEM), d) keratinocyte serum free medium (K-SFM), e) EndoGRO- IVIV medium, f) a-MEM for 48h at 37°C.
- a-MEM a-minimum essential medium
- K-SFM keratinocyte serum free medium
- f EndoGRO- IVIV medium
- Figure 8 shows the mechanical properties of GG/GGDVS, GG/GGDVS-SEQ. ID No 2, GG/GGDVS-SEQ. ID No 3, GG/GGDVS-SEQ. ID No 4, GG/GGDVS-SEQ. ID No 5 discs measured after immersion in a) phosphate buffered saline solution, b) calcium chloride, c) a-minimum essential medium (a-MEM), d) keratinocyte serum free medium (K-SFM), e) EndoGRO-MV medium, f) a-MEM for 48h at 37°C.
- Figure 9 shows the phenotype of human dermal microvascular endothelial cells within different formulations of GG/GGDVS-SEQ. ID No 2 inks.
- Figure 10 shows the morphology of human dermal fibroblasts within different formulations of GG/GGDVS-SEQ. ID No 2 inks.
- Figure 11 shows the morphology of human dermal fibroblasts within GG/GGDVS- SEQ. ID No 2 ink (formulation C) in co-culture medium.
- Figure 12 shows human adipose stem cells within GG/GGDVS-SEQ. ID No 1 inks.
- Figure 13 shows human keratinocytes on GG/GGDVS-SEQ. ID No 3 inks.
- the present disclosure relates to bio-instructive gellan gum-based inks, the method of preparation and uses thereof. Particularly, the present disclosure relates to the development of a bio-instructive gellan gum-based ink for 3D printing, preferably for 3D bioprinting.
- ink refers to materials of synthetic or natural origin whose properties, particularly the rheological and mechanical properties, are suitable for 3D printing. When the ink is combined with cells, it is referred as "bioink”.
- cells refers to a variety of cells from human or animal origin, such as, but not limited to, cell lines, primary cells, progenitor cells, pluri and multipotent stem cells.
- biological performance refers to the cellular activity that includes, but is not limited to, cell viability, proliferation, adhesion, spreading, differentiation, signaling, and tissue repair and regeneration including processes such as, but not limited to, inflammation, angiogenesis, extracellular matrix remodeling.
- biological moiety refers to any molecule that has any beneficial or adverse effect on a cell, tissue or living organism.
- the molecules include, but are not limited to, an antiseptic agent, an antipyretic agent, an anesthetic agent, a therapeutic agent, growth factors, antibodies, antibiotics, anti-microbial, anti-fungi, antimycotic, anti-inflammatory factors, enzymes, metallic elements, growth hormones, cytokines, interleukins, chemokines, angiogenic factors, anti-angiogenic factors, anticoagulants, contrasting agents, chemotherapeutic agents, signaling pathway molecule, a cell receptor, cell ligand.
- viscosity refers to the mechanical property of a polymeric solution that represents its resistance to flow or, in other terms, is the ratio between applied shear stress and deformation.
- crosslinking refers to the process of forming bonds between polymeric chains.
- the crosslinking may be defined as covalent (covalent bonds between the chains) and physical (physical bonds between the chains).
- Covalent crosslinking can be activated by a chemical reagent or light (photocrosslinking).
- Physical crosslinking can be activated by a change in temperature (thermal crosslinking) or by the addition of ions (ionic crosslinking).
- crosslinker refers to the agent used to promote the crosslinking process.
- the crosslinking process results in the conversion of the ink into a hydrogel i.e. the ink is convertible into a hydrogel.
- 3D printing refers to the process of building a three-dimensional object from a computer-aided design (CAD) model. It involves the successive deposition of an ink, layer by layer, in an automated and reproducible manner.
- CAD computer-aided design
- bioprinting or simply “bioprinting” refers to the process of 3D printing involving the successive deposition of a bioink, a particular form of ink.
- 3D printer refers to the equipment used for 3D printing
- 3D bioprinter refers to the equipment used for 3D bioprinting.
- the 3D printer can also be used for 3D bioprinting.
- the term “3D printer” will be used to refer to "3D printer” and "3D bioprinter”.
- extrusion-based associated to "printing” or “bioprinting” refers a specific process of 3D printing/3D bioprinting that involves the deposition of continuous inks/bioinks that together can make up individual layers and layered constructs.
- co-axial-based associated to "printing” or “bioprinting” refers to a specific process of 3D printing/3D bioprinting that involves the separate dispensing of two or more inks/bioinks through different syringes, that are united in a final (co-axial) nozzle, leading to the extrusion of a single fiber.
- the bio-instructive gellan gum-based ink comprise a gelifying material and a bio-instructive material.
- the gelifying material is gellan gum as this material is able to crosslink and form hydrogels at mild conditions, at a temperature ranging from 4°C to 50°C, and with the addition of mono- or divalent cations (e.g. calcium, sodium, potassium).
- mono- or divalent cations e.g. calcium, sodium, potassium
- gellan gum is selected from low-acyl gellan gum, high acyl gellan gum, or a mixture of these.
- the concentration of gellan gum ranges from 0.4 to 2.4 % (m/vink), preferably from 0.5 to 1.25 % (m/vink).
- the bio-instructive material is a chemically-modified gellan gum linked to a biological moiety that instructs a biological performance.
- the biological moiety can be a peptide, a combination of peptide(s), a combination of peptide(s) and other components, a protein, a combination of proteins, or a combination of proteins and other components.
- Other components can be polymers, polysaccharides, glycosaminoglycans, or proteoglycans.
- the bio-instructive material comprises one or more biological moieties or mixtures thereof.
- a chemically-modified gellan gum is used to allow the link of biological moieties.
- gellan gum is chemically modified with divinyl sulfone allowing the chemical binding of any cysteine-containing peptide.
- gellan gum can be chemically modified with carbodiimides or periodate, that also allow the binding between GG and one or more peptides. Regardless the nature of the chemical modification, the chemically-modified gellan gum with the cysteine-containing peptide can induce a biological performance, and therefore be used as a bio-instructive material.
- the degree of modification of the divinyl sulfone-modified gellan gum ranges from 5 to 100%, preferably 25 to 100%.
- the peptide sequences are selected from proteins comprising extracellular matrix proteins, growth factors, enzymes, growth hormones, cytokines, antibodies, anti-inflammatory factors, angiogenic factors, anti-angiogenic factors, signalling pathway molecules, cell receptors and cell ligands.
- peptide sequences from extracellular matrix proteins such as SEQ. ID No 2 (peptide sequence derived from fibronectin protein), SEQ. ID No 1 (peptide sequence derived from fibronectin protein), SEQ. ID No 3 (peptide sequence derived type IV collagen protein), SEQ. ID No 4 (peptide sequence derived from fibronectin protein), SEQ. ID No 5 (peptide sequence derived from laminin 1-derived) are chemically bound to chemically modified gellan gum to promote cell adhesion.
- the composition of the peptide sequences is described in Table 2.
- peptide sequences from extracellular matrix proteins like SEQ. ID No 6 (peptide sequence derived from the Mefp3 protein from mussels); SEQ. ID No 7 (peptide sequence derived from the Mefp5 protein from mussels) are chemically bound to chemically modified gellan gum to improve the adhesive properties of the material.
- SEQ. ID No 6 peptide sequence derived from the Mefp3 protein from mussels
- SEQ. ID No 7 peptide sequence derived from the Mefp5 protein from mussels
- the composition of the peptide sequences is described in Table 2.
- peptide sequences from extracellular matrix proteins like SEQ. ID No 13 (peptide sequence derived from the resilin protein), SEQ. ID No 14 (peptide sequence derived from the resilin protein), SEQ. ID No 15 (peptide sequence derived from the elastin protein), SEQ. ID No 16 (peptide sequence derived from the elastin protein), SEQ. ID No 17 (peptide sequence derived from the elastin protein) are chemically bound to chemically modified gellan gum for crosslinking and to improve the elastic properties of the material.
- the composition of the peptide sequences is described in Table 9.
- peptide sequences comprising active sites for metalloproteinases degradation like SEQ.
- peptide sequences containing at least two cysteines are used to crosslink the chemically-modified gellan gum.
- the crosslinker material allows the crosslinking of the gellan gum at mild conditions, forming a hydrogel.
- peptide sequences comprise at least a sequence 90% identical to the sequences of the following list: SEQ. ID No 1, SEQ. ID No 2, SEQ. ID No 3, SEQ. ID No 4, SEQ. ID No 5, SEQ ID No 6, SEQ. ID No 7, SEQ. ID No 8, SEQ. ID No 9, SEQ. ID No 10, SEQ. ID No 11, SEQ. ID No 12, SEQ. ID No 13, SEQ. ID No 14, SEQ. ID No 15, SEQ. ID No 16, SEQ. ID No 17 or mixtures thereof. Preferably 96% identical, 97% identical, 98% identical, 99% identical or identical.
- the composition of the peptide sequences is described in Table 2 and 9.
- Methods for the alignment of sequences for comparison are well known in the art, such methods include GAP, BESTFIT, BLAST, FASTA and TFASTA.
- GAP uses the algorithm of Needleman and Wunsch ((1970) J Mol Biol 48: 443-453) to find the global (over the whole the sequence) alignment of two sequences that maximizes the number of matches and minimizes the number of gaps.
- the BLAST algorithm (Altschul et al. (1990) J Mol Biol 215: 403-10) calculates percent sequence identity and performs a statistical analysis of the similarity between the two sequences.
- the software for performing BLAST analysis is publicly available through the National Centre for Biotechnology Information (NCBI).
- the peptide concentration ranges from 0.0002 to 15 M, preferably 0.0007 to 10 M.
- the rheological properties of bio-instructive gellan gumbased inks are only slightly modified by the alteration of the cysteine-containing peptide. This allows the use of similar printing settings for the same ink formulation independently of the peptide used.
- the viscosity of the bio-instructive gellan gum-based ink at 37°C ranges from 0.01 to 300000 Pa.s.
- the shear storage modulus of the bio-instructive gellan gumbased ink decreases by increasing the temperature.
- the bio-instructive gellan gum-based ink is able to encapsulate and/or support cells, forming bioinks that can be used for bioprinting.
- An aspect of the present disclosure describes an ink comprising:
- a method of preparing the bio-instructive gellan gum-based ink comprising the following steps: (i) dissolving a divinyl sulfone-modified gellan gum in distilled water or a suitable buffer with pH above 8.2, preferably in distilled water containing 0.5M of sucrose; (ii) reacting the dissolved divinyl sulfone-modified gellan gum with a peptide sequence for 1 hour at 20-25°C, preferably 25°C; (iii) optionally, dissolving an unmodified gellan gum in a suitable buffer, preferably in distilled water, at 90°C under stirring for 15-60 minutes, preferably for 30 minutes, and mixing the dissolved gellan gum with the dissolved divinyl sulfone-modified gellan gum reacted with a peptide sequence, in a 1:1 (v:v) ratio, at a temperature between 4-50°C.
- the gelifying material and the bio-instructive material are mixed at physiological mild conditions (5-37°C) at a preferred volume:volume ratio of 1:1.
- the gelifying material and the bio-instructive material are mixed at concentrations that can vary from 0.5% to 2.5% (w/vink) at a preferred ratio of 2:1 (mass:mass) of gelifying material to bio-instructive material.
- the concentration of the divinyl sulfone-modified gellan gum ranges from 0.1 to 2.5 % (m/vink), preferably from 0.25 to 1 % (m/vink).
- the volume ratio between the unmodified gellan gum and the divinyl sulfone-modified gellan gum is 0.5:l-l:0.5, preferably 1:1.
- the mass ratio between the unmodified gellan gum and the gellan gum- divinyl sulfone is 2:1-1:2, preferably 2:1.
- the method further comprises the step of mixing the bio-instructive gellan gum-based ink with a cell pellet or a solution containing cells, at a temperature between 4-37°C.
- the cell pellet or the solution containing cells comprises non-human animal cells, human cells, stem cells, cell lines, primary cells, progenitor cells or mixtures thereof.
- the suitable buffer used in the preparation of the ink can be selected from the following list: Triethanolamine, Tris-acetate-EDTA, Tris base, tricine, bicine, diglycine, 4-(2-Hydroxyethyl)-l-piperazinepropanesulfonic acid, 4-(2- Hydroxyethyl)piperazine-l-propanesulfonic acid, N-(2-Hydroxyethyl)piperazine-N'-(3- propanesulfonic acid) (HEPES), N-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid, [(2-Hydroxy-l,l-bis(hydroxymethyl)ethyl)amino]-l-propanesulfonic acid (TAPS), 2- Amino-2-methyl-l,3-propanediol, Ammediol (AMPD), N-(l,l-Dimethyl-2-hydroxyethyl)- 3-
- the ink crosslinks into a hydrogel by decreasing the temperature bellow 90°C.
- the gelation temperature ranges from 4°C to 90°C, preferably from 4°C to 50°C.
- the ink crosslinks into a stable hydrogel by contact with aqueous ionic solutions, preferably phosphate buffered saline, cell culture media, or mixtures thereof.
- aqueous ionic solutions preferably phosphate buffered saline, cell culture media, or mixtures thereof.
- the ink crosslinks into a hydrogel upon contact with a peptide containing at least two cysteines, preferably a peptide selected from the following list: SEQ. ID No 8, SEQ. ID No 9, SEQ. ID No 10, SEQ. ID No 11, SEQ. ID No 12, SEQ. ID No 13, SEQ. ID No 14, SEQ. ID No 15, SEQ. ID No 16, SEQ. ID No 17, or mixtures thereof.
- a peptide selected from the following list: SEQ. ID No 8, SEQ. ID No 9, SEQ. ID No 10, SEQ. ID No 11, SEQ. ID No 12, SEQ. ID No 13, SEQ. ID No 14, SEQ. ID No 15, SEQ. ID No 16, SEQ. ID No 17, or mixtures thereof.
- the composition of the peptide sequences is described in Table 9.
- a “stable hydrogel” is a hydrogel with defined structure, and with a shear storage modulus higher than the shear loss modulus.
- the "gelation temperature”, or “sol-gel temperature” is the temperature where the hydrogel crosslinking occurs, thus converting the ink into a stable hydrogel.
- the shear storage modulus ranges from 10 to 10000 Pa.
- the bio-instructive gellan gum-based ink is printable using a standard 3D printer.
- the bio-instructive gellan gum-based ink is printable using an extrusion-based 3D printer. In a further embodiment, the bio-instructive gellan gum-based ink is printable using a co-axial 3D printer.
- the bio-instructive gellan gum-based ink can be used to produce an article, preferably an article obtained by 3D printing.
- the article is a three- dimensional or two-dimensional polymeric network, in the dried or wet state, that can be a product for Tissue Engineering and Regenerative Medicine purposes.
- the bio-instructive gellan gum-based ink alone, or in combination with cells can be used to print bio-instructive biomaterials or tissue-like substitutes for the repair/regeneration of tissue defects or/and of diseased tissues or/and organs, such as for the treatment of wounds.
- bio-instructive gellan gum-based ink alone, or in combination with cells can be used to print tissues or/and organs models for the in vitro study of diseases or/and drug screening.
- the present disclosure also relates to a kit comprising the ink described in any of the embodiments of the present disclosure.
- the ink can be in a reservoir configured to be used in a 3D printer.
- GG/GGDVS inks are prepared by combining different amounts of GG and GGDVS functionalized with peptide(s) (Table 1 and 2).
- GGDVS is prepared by reacting GG with divinyl sulfone (with an excess molar ratio of divinyl sulfone) for lh, under stirring, at room temperature (20-25°C), at pH 12. After reaction, the GGDVS is purified through precipitation in diethyl ether and dialysis against dHzO. Dried GGDVS is obtained by freeze-drying.
- the resulting material is then reacted with 800 pM of a peptide (Table 2) for lh at room temperature (20-25°C).
- GG is dissolved in dHzO at 90 C under stirring for 30 min. After this period, both solutions are mixed at 1:1 ratio (v:v) at a temperature between 4-40 'C to achieve the final concentrations described on Table 1.
- the amount of peptide conjugated to the GGDVS can be quantified by the micro bicinchoninic acid (micro BCA) protein assay.
- micro BCA micro bicinchoninic acid
- peptide standard dilutions are prepared in Milli-Q® H2O at different dilutions 200, 40, 20, 10, 5, 2.5 and 1 pg/ml and the GGDVS-peptide is prepared in Milli-Q® H2O at 1 mg/mL.
- Each sample is then reacted with a working reagent for 2h at 37°C, and the absorbance measured at 562 nm with a microplate reader (BioTek, USA).
- the percentage of conjugation efficiency is given by the ratio between the peptide amount calculated from the micro-BCA assay and the peptide amount used to react with GGDVS multiplied by 100.
- the amount of peptide conjugated to the GGDVS was quantified by the micro bicinchoninic acid (micro BCA) protein assay and is presented in Table 3.
- Table 3 Efficiency of peptide conjugation to GGDVS, determined by micro-BCA.
- the rheological properties of the GG/GGDVS ink can be determined using a Kinexus Pro from Malvern (serial number MAL1097376), coupled with a conical geometry.
- the rheological behaviour of the GG/GGDVS and GG/GGDVS- SEQ. ID No 2 inks was determined and is plotted in Figure 1. Shear viscosity was recorded along a range of 0.1-100 s 1 of shear rate, at 37°C ( Figure la and lc).
- Inks showed a nonNewtonian behaviour as the viscosity of the inks was dependent on the shear rate, as well as, a shear-thinning behaviour as the viscosity of the inks decreased with increasing shear rates.
- shear viscosity of inks increased with the amount of polymer existing in the ink formulation, i.e. increasing from the formulation A to D.
- Shear viscosity was recorded along a range of 0.1-100 s 1 of shear stress, at 37°C ( Figure lb and Id). Whereas the viscosity of formulation A was constant for increasing shear stresses in the tested range of 0.1 - 100 Pa, the viscosity of formulations B, C and D was high at low shear stress and a breakdown of the inner structural skeleton and drop of viscosity occurred at increasing shear stress. In addition, it is evident that the shear viscosity increased with the amount of polymer existing in the ink formulation, i.e. increasing from the formulation A to D. These results validate the possibility of extruding inks at higher shear stresses, where the viscosity is lower.
- Table 4 presents the average values of yield stress, flow consistency index and flow behaviour index of GG/GGDVS inks and GG/GGDVS-SEQ. ID No 2 inks.
- the Yield stress was calculated by the intersection of the curve fitted to the plateau region and the curve fitted to the steeply declining region of shear stress/viscosity curves. The shear stress at the point of intersection corresponds to the yield stress.
- shear thinning coefficients (flow consistency index and flow behaviour index) were derived from power law regression of the shear-thinning curves, according to the following equation r
- Ky 71-1 ; where q is viscosity, y is the shear rate, K is the flow consistency index and n is the flow behaviour index.
- Table 4 Average values of yield stress, flow consistency index and flow behaviour index of GG/GGDVS inks and GG/GGDVS-SEQ. ID No 2 inks.
- the rheological behaviour of the GG/GGDVS inks was further assessed at decreasing temperatures ( Figure 2).
- the shear storage (G') and shear loss (G") moduli were recorded within a temperature ramp from 60°C to 5°C (2°C min- 1 ), with constant shear of 1.6 Hz and 0.5 % target shear strain (Figure 2).
- the sol-gel transition temperature was identified by the intersection of G' and G", temperature at which occurs the transition of the inks from the liquid (G' ⁇ G") to the solid (G' > G") state.
- a sol-gel transition was only detected for the formulation A and B, as intersection of G' and G" only occurred within the tested temperature range for these two formulations.
- the storage modulus was higher than the loss modulus at all temperatures tested, indicating that the sol-gel transition occurs at temperatures above 60°C.
- Table 5 presents the viscosity at 20°C and 37°C, the gelation temperature and the shear storage modulus of GG/GGDVS inks.
- the gelation temperature was calculated from the temperature ramps, at the intersection of G' and G".
- the shear storage modulus was calculated from the time sweeps, at the plateau when G'>G".
- ink mechanics were standardized by a 5 min initial shearing at 100 s 1 followed by 10 min of resting. The values are displayed as mean 1 standard deviation.
- Table 5 Average values of viscosity at 20°C and 37°C, gelation temperature and shear storage modulus of GG/GGDVS inks.
- the force needed to extrude GG/GGDVS inks can be measured using a Legato® 100 syringe pump (KD Scientific, Holliston, USA). The force needed to extrude GG/GGDVS inks was measured at 37°C using either a 20-gauge or 27- gauge needle (Figure 4).
- the flow rate (mL.min -1 ) was set according to the needle diameter. Force measurements were performed in triplicate during 1 min of extrusion and the mean force during that time interval was used for analysis.
- the force used to extrude was nearly 10 N, independently of the ink formulation (A, B, C or D) and independently of the printing speed (10 or 20 mmsec -1 ).
- the force used to extrude was dependent on the ink formulation, as it increased from 10 N (formulation A and B) to nearly 20-25 N (formulation C and D). No significant effects were detected at different printing speeds (10 or 20 mmsec -1 ).
- the GG/GGDVS inks can be printed using 3D printers.
- GG/GGDVS inks were printed using an extrusion-based printer.
- the extrusion velocity was set to 5 mm sec -1 .
- the temperature of the printer was settled at 20°C for inks A and B, and at 37°C for inks C and D.
- GG/GGDVS inks were sprayed with a CaC solution (100 mM) during printing for ionic crosslinking to occur and then immersed in cell culture medium for 24h for stabilization.
- Figure 5 shows the GG/GGDVS fibres printed using an extrusion-based printer and the settings defined before. The thickness of the fibres was measured by ImageJ software at different points of the fibres and is displayed as mean 1 standard deviation on Table 6.
- Table 6 Thickness of the printed GG/GGDVS fibres.
- Figure 6 shows the GG/GGDVS discs (10 mm of diameter; 5 mm of height) printed using an extrusion-based printer and the settings defined before. The dimensions of the discs were determined after swelling in cell culture medium for 24h and are described in Table 7. Table 7: Dimensions of the printed GG/GGDVS discs after 24h of swelling
- the mechanical properties of hydrogel discs were measured using the Instron 5543 (Instron Int. Ltd., USA) mechanical testing device, after immersion in distinct solutions for 48h at 37°C. Hydrogel discs were placed on the base platform of the device, compressed at 1 mm.s 4 , and the ratio of compressive stress to strain was measured. The Young's Modulus was calculated in the loglO linear region (0 - 5 % compressive strain). Results are plotted in Figure 8.
- GG/GGDVS inks have been defined to be used for skin engineering.
- the human skin is composed by two main layers: the dermis and the epidermis.
- the dermis is mainly composed by fibroblasts and the epidermis composed of keratinocytes.
- One of the main proteins of the extracellular matrix existing in the dermis is the fibronectin and in the epidermis is the collagen IV.
- a human skin equivalent can be engineered by using two GG/GGDVS inks that specifically represent the cells and extracellular matrix proteins of each layer: the dermis using human dermal fibroblasts loaded in GG/GGDVS-SEQ. ID No 2 (formulation C, from previous Table 1) inks (bioinks) and the epidermis using human keratinocytes on GG/GGDVS-SEQ. ID No 3 (formulation A, from previous Table 1) inks (bioinks).
- the peptide SEQ. ID No 2 encloses a RGD cell adhesive sequence existing in the fibronectin and the peptide SEQ. ID No 3 is a cell adhesive sequence existing in collagen IV.
- the engineered skin equivalents can be used as skin models for high- throughput screening or for skin wound repair/regeneration.
- a dermis equivalent was obtained using human dermal fibroblasts loaded in GG/GGDVS-SEQ. ID No 2 (formulation C, from previous Table 1) inks (bioinks) after 21 days of culture in standard culture medium.
- Human dermal fibroblasts were isolated from the human skin of adult healthy donors who underwent abdominoplasties under standard protocols.
- 1 mL of GG/GGDVS-SEQ. ID No 2 ink was homogeneously and gently mixed with cell pellets containing 1 x 10 6 cells at 37°C.
- Cell-laden hydrogels (according to Table 1) were formed after dispensing the bionk into the cell culture plate at 25°C.
- Cell-laden hydrogels were further cultured up to 21 days in a-MEM cell culture medium (Thermo Fisher Scientific, USA) supplemented with 10 % of fetal bovine serum (GibcoTM, Thermo Fisher Scientific, USA) and 10 % of antibiotics/antimycotics (Life Technologies Corporation, USA).
- Cell morphology ( Figure 10) was visualized under a confocal microscope after F-actin staining with Phalloidin-TRITC (0.01 mg/mL, SIGMA, USA) and nuclei counter-staining with 4',6-diamidino-2-phenylindole (DAPI, 0.02 mg/mL).
- formulation C (Ink C) promoted better cell adhesion and spreading than formulations A, B and D (Ink A, B and D).
- the cells in the formulation C (Ink C) proliferated along the time.
- a dermis equivalent was obtained using human dermal fibroblasts loaded in GG/GGDVS-SEQ. ID No 2 (formulation C, from previous Table 1) inks (bioinks) after 21 days of culture in endothelial cell culture medium.
- 1 mL of GG/GGDVS-SEQ. ID No 2 ink (formulation C, as stated in Table 1) was homogeneously and gently mixed with cell pellets of human dermal fibroblasts containing 1 x 10 6 cells at 37°C. Hydrogels were formed after dispensing the cell-laden ink into the cell culture plate at 25°C.
- Cell-laden hydrogels were further cultured up to 14 days in 1:1 (v:v) mixture of a-MEM cell culture medium (Thermo Fisher Scientific, USA) supplemented with 10 % of fetal bovine serum (GibcoTM, Thermo Fisher Scientific, USA) and 10 % of antibiotics/antimycotics (Life Technologies Corporation, USA) and endothelial growth medium EGM-2 MV (Lonza, USA).
- a-MEM cell culture medium Thermo Fisher Scientific, USA
- fetal bovine serum GibcoTM, Thermo Fisher Scientific, USA
- EGM-2 MV endothelial growth medium
- An epidermis equivalent layer was obtained using human keratinocytes on GG/GGDVS-SEQ. ID No 3 (formulation A, from previousTable 1) inks (bioinks).
- Human keratinocytes were isolated from the human skin of adult healthy donors who underwent abdominoplasties under standard protocols.
- GG/GGDVS-SEQ. ID No 3 (formulation A, from previous Table 1) ink was homogeneously and gently mixed at 37°C. Hydrogels were formed after dispensing the ink into the cell culture plate at 25°C.
- GG/GGDVS inks are defined to be used for tissue repair and regeneration. Accomplishment of tissue regeneration greatly depends on a fast neovascularization post-implantation. Stem cells and endothelial cells present a great angiogenic potential owed to their angiogenic secretome. Endothelial cells have also the ability to pre-vascularize engineered tissue-like constructs which is an added potential as it can benefit inosculation with the host tissue.
- a pre-vascularized tissue-like construct can be engineered combining two bioinks: human dermal microvascular endothelial cells loaded in GG/GGDVS-SEQ. ID No 2 (formulation C, as described in Table 1) bioink and human adipose stem cells loaded in GG/GGDVS-SEQ. ID No 1 (formulation D, as described in Table 1) bioink.
- the ink GG/GGDVS-SEQ. ID No 2 (formulation C) loaded with human dermal microvascular endothelial cells can be printed in a tree-like network in between the GG/GGDVS-SEQ. ID No 1 (formulation D) ink loaded with human adipose stem cells.
- the engineered constructs can be transplanted to wounded tissues for repair or regeneration.
- a tissue containing endothelial cells was obtained using human dermal microvascular endothelial cells loaded in GG/GGDVS-SEQ. ID No 2 (formulation C, as described in Table 1) bioink.
- Human dermal microvascular endothelial cells were isolated from the human skin of adult healthy donors who underwent abdominoplasties under standard protocols.
- 1 mL of GG/GGDVS-SEQ. ID No 2 ink (as described in Table 1) was homogeneously and gently mixed with cell pellet containing l x 10 6 cells at 37°C.
- Cell-laden hydrogels were formed after dispensing the bioink into the cell culture plate at 25°C.
- a tissue containing stem cells was obtained using human adipose stem cells loaded in GG/GGDVS-SEQ. ID No 1 (formulation D, as described in Table 1) bioink.
- Human adipose stem cells were isolated from the human adipose tissue of adult healthy donors who underwent abdominoplasties under standard protocols.
- 1 mL of GG/GGDVS SEQ. ID No 1 (formulations A and D, as described in Table 1) was homogeneously and gently mixed with cell pellets containing 1 x 10 6 cells at 37°C. Hydrogels were formed after dispensing the bioink into the cell culture plate at 25°C.
- GGDVS inks can be prepared by combining divinyl sulfone modified gellan gum (GGDVS) (component A) and a peptide crosslinker sequence (component B, Table 9) to attain hydrogels with different percentages of crosslinking densities (Table 8).
- GGDVS divinyl sulfone modified gellan gum
- component B peptide crosslinker sequence
- a hydrogel is formed when both components A and B are mixed.
- a peptide sequence (10% in volume, Table 2) is linked to GGDVS by adding it to the GGDVS solution and let to react under stirring for lh at room temperature (20-25°C). In the present example the amount of peptide used was 0.8 M.
- Table 8 shows examples of GGDVS ink formulations, by altering the crosslinking density.
- the quantity of the peptide crosslinker sequence (mol) used is half of the moles of GGDVS.
- the other crosslinking densities are calculated from the latest, i.e. the quantity of the peptide crosslinker to crosslink 50% of GGDVS crosslinker is half of the quantity needed of the peptide crosslinker to crosslink 100% of GGDVS.
- the rheological properties of GGDVS inks can be determined using a Kinexus Pro from Malvern (serial number MAL1097376), coupled with a conical geometry.
- the alteration of the behaviour of the ink from liquid to solid was followed using rheological measurements ( Figure 3), using formulations e, f and g (table 8) crosslinked with SEQ ID No 14.
- the shear storage (G') and loss (G") moduli were recorded for 800 secs at 37°C, with constant shear of 1.6 Hz and 0.5 % target shear strain.
- G" modulus values ranged between 1 and 5 Pa (not visible in the graphic).
- the sol-gel transition occurred immediately after mixing component A and B, and hence it is not evident in the graphics.
- shear storage modulus increased along the time, indicating that the process is still occurring, until it reaches a plateau, indicating that the process of crosslinking finished. It is evident that formulations with higher crosslinking density (from e to g) present higher shear storage modulus.
- GGDVS inks can be printed using an extrusion co-axial printer.
- Two dispensable HSW SOFT-JECT® 5 ml single-use plastic syringes (Henke-Sass, Wolf GmbH; Tuttlingen, Germany) were loaded with the GGDVS ink components: A) one syringe is loaded with the GGDVS solution (5 to 15 mg/ml) with/without cells and B) another syringe is loaded with the peptide crosslinker solution, according to the crosslinking densities described on Table 8.
- the mixer is settled to print 1 part of the component A per 4 parts of the component B.
- the extrusion velocity is set to 5 mm/sec and the temperature of the printer is settled at 37°C.
- GGDVS inks have been defined to be used for printing hydrogels for tissue repair and regeneration.
- the delivery of growth factors and cytokines is recognized as an appealing strategy in tissue repair and regeneration.
- a biomaterial containing chemical mediators can be engineered to present 1) different gradients of degradation or 2) different degradation specificity, in order that the encapsulated chemical mediator is released in pair with the biomaterial degradation.
- constructs with different gradients of biodegradation are formed by combining a bioactive molecule of interest (such as epidermal growth factor), the GGDVS ink (1%, m/vink) and the peptide SEQ. ID No 10 as crosslinker sensitive to MMP-13 cleavage.
- a bioactive molecule of interest such as epidermal growth factor
- the GGDVS ink 1%, m/vink
- the peptide SEQ. ID No 10 as crosslinker sensitive to MMP-13 cleavage.
- GGDVS ink (formulation e from previous Table 7) is used to print the first layer
- GGDVS ink (formulation f, from previous Table 7) is used to print the second layer
- GGDVS ink (formulation g, from previous Table 7 is used to print the third layer)
- GGDVS ink (formulation h, from previous Table 7 is used to print the fourth layer, in order to have a construct with different levels of degradation by metalloproteinase (Formulation e > Formulation h; Lower degradation > Higher degradation).
- constructs with different biodegradation sensitivities are formed by combining the bioactive agent of interest, the GGDVS ink (1%, m/vink) and the peptide SEQ. ID No 10 as crosslinker sensitive to MMP-13 cleavage and the peptide SEQ. ID No 9 as crosslinker sensitive to MMP-2 cleavage.
- the type of crosslinker is altered.
- GGDVS ink (formulation g, from previous Table 7) and the crosslinker sensitive to MIVIP-13 cleavage is used to print the first two layers
- GGDVS ink (formulation g, from previous Table 7) and the crosslinker sensitive to MMP-2 cleavage is used to print the second two layers, in order to have a construct with different specificities of degradation by metalloproteinase.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Manufacturing & Machinery (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
La présente divulgation concerne une encre comprenant une gomme gellane, non modifiée ou modifiée par du divinylsulfone ; et une séquence peptidique contenant une cystéine, le peptide étant lié à la gomme gellane par l'intermédiaire des fractions de divinylsulfone.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT11690020 | 2020-11-23 | ||
PT116900 | 2020-11-23 | ||
EP20217709.3 | 2020-12-29 | ||
EP20217709 | 2020-12-29 | ||
PT117156 | 2021-04-01 | ||
PT11715621 | 2021-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022107108A1 true WO2022107108A1 (fr) | 2022-05-27 |
Family
ID=79170788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/060867 WO2022107108A1 (fr) | 2020-11-23 | 2021-11-23 | Encres à base de gomme gellane, leur procédé d'obtention et leurs utilisations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022107108A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2244753A2 (fr) | 2008-02-15 | 2010-11-03 | Associacion for the Advancement of Tissue Engineering and Cell Based Technologies & Therapies (A4TEC) | Hydrogels à base de gomme gellane pour des applications de médecine régénérative et d'ingénierie tissulaire, son système et ses dispositifs de traitement |
CN106474560A (zh) | 2016-11-04 | 2017-03-08 | 暨南大学 | 一种用于3d生物打印的水凝胶材料及其制备方法与应用 |
KR20180035162A (ko) | 2016-09-28 | 2018-04-05 | 포항공과대학교 산학협력단 | 신규한 3d 바이오 프린팅용 바이오 잉크 및 이의 이용 |
WO2018191244A1 (fr) | 2017-04-10 | 2018-10-18 | TheWell Bioscience | Hydrogel pour applications biomédicales et de culture cellulaire |
-
2021
- 2021-11-23 WO PCT/IB2021/060867 patent/WO2022107108A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2244753A2 (fr) | 2008-02-15 | 2010-11-03 | Associacion for the Advancement of Tissue Engineering and Cell Based Technologies & Therapies (A4TEC) | Hydrogels à base de gomme gellane pour des applications de médecine régénérative et d'ingénierie tissulaire, son système et ses dispositifs de traitement |
KR20180035162A (ko) | 2016-09-28 | 2018-04-05 | 포항공과대학교 산학협력단 | 신규한 3d 바이오 프린팅용 바이오 잉크 및 이의 이용 |
CN106474560A (zh) | 2016-11-04 | 2017-03-08 | 暨南大学 | 一种用于3d生物打印的水凝胶材料及其制备方法与应用 |
WO2018191244A1 (fr) | 2017-04-10 | 2018-10-18 | TheWell Bioscience | Hydrogel pour applications biomédicales et de culture cellulaire |
Non-Patent Citations (4)
Title |
---|
ALTSCHUL ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10 |
CAMPANELLA ET AL., BMC BIOINFORMATICS, vol. 4, 10 July 2003 (2003-07-10), pages 29 |
DA SILVA LUCÍLIA P. ET AL: "Gellan Gum Hydrogels with Enzyme-Sensitive Biodegradation and Endothelial Cell Biorecognition Sites", ADVANCED HEALTHCARE MATERIALS, vol. 7, no. 5, 1 March 2018 (2018-03-01), DE, pages 1700686, XP055901250, ISSN: 2192-2640, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fadhm.201700686> DOI: 10.1002/adhm.201700686 * |
NEEDLEMANWUNSCH, J MOL BIOL, vol. 48, 1970, pages 443 - 453 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dorishetty et al. | Bioprintable tough hydrogels for tissue engineering applications | |
Li et al. | 3D bioprinting of highly thixotropic alginate/methylcellulose hydrogel with strong interface bonding | |
CN110240712B (zh) | 一种组织粘合用的高拉伸、高粘性、自愈合双网络水凝胶及其制备方法和应用 | |
US11414556B2 (en) | Nanocomposite ionic-covalent entanglement reinforcement mechanism and hydrogel | |
Chen et al. | Injectable self-crosslinking HA-SH/Col I blend hydrogels for in vitro construction of engineered cartilage | |
Feng et al. | Assembling microgels via dynamic cross-linking reaction improves printability, microporosity, tissue-adhesion, and self-healing of microgel bioink for extrusion bioprinting | |
US11998658B2 (en) | Injectable porous hydrogels | |
EP2983727B1 (fr) | Hydrogel de type spongieux de gomme de gellane, sa préparation et ses applications biomédicales | |
Chen et al. | 3D bioprinting dermal-like structures using species-specific ulvan | |
Ansar et al. | Challenges and recent trends with the development of hydrogel fiber for biomedical applications | |
Ramakrishnan et al. | Exploring the potential of alginate-gelatin-diethylaminoethyl cellulose-fibrinogen based bioink for 3d bioprinting of skin tissue constructs | |
CN111632198A (zh) | 一种自交联透明质酸和明胶复合水凝胶注射剂及其制备方法和应用 | |
EP3165240A1 (fr) | Matériau d'échafaudage dérivé de polymère naturel et leurs procédés de production | |
Sakai et al. | One-step FRESH bioprinting of low-viscosity silk fibroin inks | |
US9173969B2 (en) | Biomaterial for wound healing | |
Wu et al. | Extracellular matrix (ECM)-inspired high-strength gelatin-alginate based hydrogels for bone repair | |
Geng et al. | Silk fibroin/polyacrylamide-based tough 3D printing scaffold with strain sensing ability and chondrogenic activity | |
Parimala Chelvi Ratnamani et al. | A comprehensive assessment on the pivotal role of hydrogels in scaffold-based bioprinting | |
Veernala et al. | Cell encapsulated and microenvironment modulating microbeads containing alginate hydrogel system for bone tissue engineering | |
WO2022107108A1 (fr) | Encres à base de gomme gellane, leur procédé d'obtention et leurs utilisations | |
Łabowska et al. | Review on the Adaption of Alginate-Gelatin Hydrogels for 3D Cultures and Bioprinting. Materials 2021, 14, 858 | |
He et al. | Recent advancements of Bioinks for 3D bioprinting of Human tissues and organs | |
Zhang et al. | Rational design of viscoelastic hydrogels for periodontal ligament remodeling and repair | |
JP2022513369A (ja) | 組換えバイオポリマーベース組成物及びバイオインクとしての使用 | |
Kim et al. | Recent advances and biomedical application of 3D printed nanocellulose-based adhesive hydrogels: A review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21835371 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21835371 Country of ref document: EP Kind code of ref document: A1 |